Accro Bioscience (Accropeutics), a clinical-stage biotech focused on regulated cell death and related disease pathways, will present Phase II clinical results of AC-201 in moderate-to-severe plaque psoriasis at the European Academy of Dermatology & Venereology (EADV) Congress, September 17–20, Paris.
Presentation Details
- Abstract Type: Oral Presentation (Late Breaking Session)
- Abstract ID: LBA-5
- Title: Efficacy and Safety of a Selective Oral TYK2/JAK1 Inhibitor, AC-201, in Patients with Plaque Psoriasis: A Phase II, Randomized, Double-blinded, Placebo-Controlled Trial
- Session: D3T01.4F
- Room: Paris Nord
- Time: Friday, September 19 | 17:15 – 17:30
About AC-201
- Mechanism: A highly selective, potent oral small-molecule inhibitor of TYK2/JAK1, binding the pseudokinase domain (JH2) with minimal effect on JAK2/JAK2 signaling.
- Indications under development:
- Psoriasis (PsO)
- Non-infectious uveitis (NIU)
- Cutaneous lupus erythematosus (CLE) - Safety profile: Phase 1 trials in Australia and China showed AC-201 was safe, well tolerated, with no discontinuations or serious adverse events.
- Phase 2 (Psoriasis): Completed with positive efficacy and safety outcomes, supporting advancement to later-stage trials.
About Accro Bioscience
- Focus: Targeting regulated cell death and immune-mediated pathogenesis.
- Clinical pipeline:
- AC-201: Selective TYK2/JAK1 inhibitor; Phase 2 in PsO complete.
- AC-101: RIPK2 inhibitor; Ph1 completed (Australia/China), Ph1b ongoing in ulcerative colitis.
- AC-003: RIPK1 inhibitor; FDA Orphan Drug Designation for aGvHD; Ph1 complete in US/China; Ph1b ongoing in aGvHD. - Global rights: Owns worldwide IP with 25 patents issued across China, Japan, US, Korea, EU.
Why It Matters
- TYK2/JAK pathway inhibition is emerging as a transformative approach in immune-mediated inflammatory diseases.
- AC-201 offers the potential for a selective, oral treatment with fewer off-target effects than traditional JAK inhibitors.
- The EADV presentation could position Accro as a competitive player alongside Bristol Myers Squibb’s deucravacitinib and other next-generation TYK2 programs.
